OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 141 filers reported holding OCULAR THERAPEUTIX INC in Q4 2021. The put-call ratio across all filers is 1.20 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,632 | -77.6% | 1,475 | -63.2% | 0.00% | – |
| Q2 2023 | $20,661 | -20.8% | 4,012 | -19.1% | 0.00% | – |
| Q1 2023 | $26,084 | +86.3% | 4,957 | +4.9% | 0.00% | – |
| Q4 2022 | $14,000 | -30.0% | 4,725 | -2.1% | 0.00% | – |
| Q3 2022 | $20,000 | +33.3% | 4,825 | +29.5% | 0.00% | – |
| Q2 2022 | $15,000 | -16.7% | 3,725 | 0.0% | 0.00% | – |
| Q1 2022 | $18,000 | -82.9% | 3,725 | -75.3% | 0.00% | – |
| Q4 2021 | $105,000 | +128.3% | 15,076 | +229.5% | 0.00% | – |
| Q3 2021 | $46,000 | -4.2% | 4,576 | +35.5% | 0.00% | – |
| Q2 2021 | $48,000 | +17.1% | 3,376 | +35.0% | 0.00% | – |
| Q1 2021 | $41,000 | +241.7% | 2,501 | +316.1% | 0.00% | – |
| Q4 2020 | $12,000 | +33.3% | 601 | -47.7% | 0.00% | – |
| Q3 2020 | $9,000 | +28.6% | 1,150 | +27.8% | 0.00% | – |
| Q2 2020 | $7,000 | – | 900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 1,932,607 | $40,643,000 | 15.56% |
| Lamond Capital Partners LLC | 711,533 | $14,964,000 | 15.19% |
| Polaris Venture Management Co. V, L.L.C. | 1,230,009 | $25,867,000 | 11.54% |
| NOTTINGHAM ADVISORS, INC. | 171,985 | $3,617,000 | 0.60% |
| Portolan Capital Management | 122,518 | $2,577,000 | 0.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 160,000 | $3,365,000 | 0.33% |
| Rotella Capital Management, Inc. | 18,461 | $388,000 | 0.32% |
| Monashee Investment Management LLC | 28,834 | $606,000 | 0.29% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 335,498 | $7,056,000 | 0.24% |
| BAILARD, INC. | 55,000 | $1,157,000 | 0.18% |